Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data

International Journal of Antimicrobial Agents

Volumn 33, Issue 3, 2009, Pages 194-200

  Sendzik, Judith ^a   Lode, Hartmut ^a   Stahlmann, Ralf ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Arthropathy; Paediatrics; Quinolones

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PEFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ABDOMINAL PAIN; ANTHRAX; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; BACTERIAL MENINGITIS; BONE PAIN; CHOLERA; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG WITHDRAWAL; ENTERITIS; GAIT DISORDER; HUMAN; JOINT SWELLING; LEG PAIN; LIMB PAIN; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SHORT SURVEY; SINGLE DRUG DOSE; SUPPURATIVE OTITIS MEDIA; TENDINITIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING;

ADOLESCENT; ANIMALS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; JOINT DISEASES; MALE; QUINOLONES;

EID: 60249094709     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.08.004     Document Type: Short Survey

References (51)

1. Ingham B., Brentnall D.W., Dale E.A., and McFadzean J.A. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. Toxicol Lett 1 (1977) 21-26
2. Stahlmann R. Children as a special population at risk-quinolones as an example for xenobiotics exhibiting skeletal toxicity. Arch Toxicol 77 (2003) 7-11
3. Stahlmann R. Effects on connective tissue structures. In: Hooper D.C., and Rubinstein E. (Eds). Quinolone antimicrobial agents. 3rd ed. (2003), ASM Press, Washington, DC 439-447
4. Lozo E., Riecke K., Schwabe R., Vormann J., and Stahlmann R. Synergistic effect of ofloxacin and magnesium deficiency on joint cartilage in immature rats. Antimicrob Agents Chemother 46 (2002) 1755-1759
5. Riecke K., Lozo E., Shakibaei M., Baumann-Wilschke I., and Stahlmann R. Fluoroquinolone-induced lesions in the epiphyseal growth plates of immature rats. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17-20 September 2000; Toronto, Canada (2000), ASM Press, Washington, DC [Abstract No. 276]
6. Channa H.M., Ashfaq M., Mastoi S.M., and Qureshi M.A. Effect of ciprofloxacin on growing cartilage in albino rat pups. J Ayub Med Coll Abbottabad 18 (2006) 50-54
7. Bristol-Myers Squibb Company. Full prescribing information, Tequin™, January 2006.
8. ®, September 2007. http://www.levaquin.com [accessed 11 August 2008].
9. Van der Linden P.D., van Puijenbroek E.P., Feenstra J., Veld B.A., Sturkenboom M.C., Herings R.M., et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum 45 (2001) 235-239
10. Vyas H., and Krishnaswamy G. Images in clinical medicine. Quinolone-associated rupture of the Achilles' tendon. N Engl J Med 357 (2007) 2067
11. van der Linden P.D., van der Lei J., Nab H.W., Knol A., and Stricker B.H. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 48 (1999) 433-437
12. Kato M., Takada S., Kashida Y., and Nomura M. Histological examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats. Toxicol Pathol 23 (1995) 385-392
13. Shakibaei M., Pfister K., Schwabe R., Vormann J., and Stahlmann R. Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet. Antimicrob Agents Chemother 44 (2000) 261-266
14. Sendzik J., Shakibaei M., Schäfer-Korting M., and Stahlmann R. Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. Toxicology 212 (2005) 24-36
15. Simonin M.A., Gegout-Pottie P., Minn A., Gillet P., Netter P., and Terlain B. Proteoglycan and collagen biochemical variations during fluoroquinolone-induced chondrotoxicity in mice. Antimicrob Agents Chemother 43 (1999) 2915-2921
16. Hayem G., Petit P.X., Levacher M., Gaudin C., Kahn M.F., and Pocidalo J.J. Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Antimicrob Agents Chemother 38 (1994) 243-247
17. Shakibaei M., Schulze-Tanzil G., de Souza P., John T., Rahmanzadeh M., Rahmanzadeh R., et al. Inhibition of mitogen-activated protein kinase kinase induces apoptosis of human chondrocytes. J Biol Chem 276 (2001) 13289-13294
18. Sheng Z., Cao X., Peng S., Wang C., Li Q., Wang Y., et al. Ofloxacin induces apoptosis in microencapsulated juvenile rabbit chondrocytes by caspase-8-dependent mitochondrial pathway. Toxicol Appl Pharmacol 226 (2008) 119-127
19. 1-integrin receptor. J Pharmacol Exp Ther 322 (2007) 155-165
20. Stahlmann R., Förster C., Shakibaei M., Vormann J., Günther T., and Merker H.J. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical with quinolone-induced arthropathy. Antimicrob Agents Chemother 39 (1995) 2013-2018
21. Förster C., Kociok K., Shakibaei M., Merker H.J., Vormann J., Günther T., et al. Integrins on joint cartilage chondrocytes and alterations by ofloxacin or magnesium deficiency in immature rats. Arch Toxicol 70 (1996) 261-270
22. Vormann J., Förster C., Zippel U., Lozo E., Günther T., Merker H., et al. Effects of magnesium deficiency on magnesium and calcium content in bone and cartilage in developing rats in correlation to chondrotoxicity. Calcif Tissue Int 61 (1997) 230-238
23. Pfister K., Mazur D., Vormann J., and Stahlmann R. Diminished ciprofloxacin-induced chondrotoxicity by supplementation with magnesium and vitamin E in immature rats. Antimicrob Agents Chemother 51 (2007) 1022-1027
24. Dolui S.K., Das M., and Hazra A. Ofloxacin-induced reversible arthropathy in a child. J Postgrad Med 53 (2007) 144-145
25. Pertuiset E., Lenoir G., Jehanne M., Douchain F., Guillot M., and Menkès C.J. Joint tolerance of pefloxacin and ofloxacin in children and adolescents with cystic fibrosis [in French]. Rev Rhum Mal Osteoartic 56 (1989) 735-740
26. Hampel B., Hullmann R., and Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J 16 (1997) 127-129
27. Schaad U.B., Wedgwood J., Ruedeberg A., Kraemer R., and Hampel B. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatr Infect Dis J 16 (1997) 106-111
28. Yee C.L., Duffy C., Gerbino P.G., Stryker S., and Noel G.J. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 21 (2002) 525-529
29. Trovan Meningitis Study Group. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 21 (2002) 14-22
30. Saha D., Khan W.A., Karim M.M., Chowdhury H.R., Salam M.A., and Bennish M.L. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. Lancet 366 (2005) 1085-1093
31. ®, October 2004.
32. Pichichero M.E., Arguedas A., Dagan R., Sher L., Saez-Llorens X., Hamed K., et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis 41 (2005) 470-478
33. Arguedas A., Sher L., Lopez E., Sáez-Llorens X., Hamed K., Skuba K., et al. Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. Pediatr Infect Dis J 22 (2003) 949-955
34. Echols R., Hamed K., Arguedas A., Dagan R., Sher L., Sáez-Llorens X., et al. Gatifloxacin therapy for children: turn on the light. Clin Infect Dis 41 (2005) 1824-1825
35. Bradley J.S., Arguedas A., Blumer J.L., Sáez-Llorens X., Melkote R., and Noel G.J. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J 26 (2007) 868-878
36. Arguedas A., Dagan R., Pichichero M., Leibovitz E., Blumer J., McNeeley D.F., et al. An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. Pediatr Infect Dis J 25 (2006) 1102-1109
37. Noel G.J., Bradley J.S., Kauffman R.E., Duffy C.M., Gerbino P.G., Arguedas A., et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 26 (2007) 879-891
38. Schaad U.B. Will fluoroquinolones ever be recommended for common infections in children?. Pediatr Infect Dis J 26 (2007) 865-867
39. Mandell L.A., Peterson L.R., Wise R., Hooper D., Low D.E., Schaad U.B., et al. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?. Clin Infect Dis 35 (2002) 721-727
40. Zoetis T., Tassinari M.S., Bagi C., Walthall K., and Hurtt M.E. Species comparison of postnatal bone growth and development. Birth Defects Res B Dev Reprod Toxicol 8 (2003) 86-110
41. Lampl M., Veldhuis J.D., and Johnson M.L. Saltation and stasis: a model of human growth. Science 258 (1992) 801-803
42. Klein K.O., Munson P.J., Bacher J.D., Cutler G.B., and Baron J. Linear growth in the rabbit is continuous, not saltatory. Endocrinology 134 (1994) 1317-1320
43. Hermanussen M., and Geiger-Benoit K. No evidence for saltation in human growth. Ann Hum Biol 22 (1995) 341-345
44. Johnson M.L., Veldhuis J.D., and Lampl M. Is growth saltatory? The usefulness and limitations of frequency distributions in analyzing pulsatile data. Endocrinology 137 (1996) 5197-5204
45. Schaad U.B., abdus Salam M., Aujard Y., Dagan R., Green S.D., Peltola H., et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 14 (1995) 1-9
46. Schaad U.B. Use of the quinolones in pediatrics. In: Andriole V.T. (Ed). The quinolones. 3rd ed. (2000), Academic Press, San Diego, CA 455-475
47. Gendrel D., Chalumeau M., Moulin F., and Raymond J. Fluoroquinolones in paediatrics: a risk for the patient or for the community?. Lancet Infect Dis 3 (2003) 537-546
48. Ghaffar F., and McCracken G.H. Quinolones in pediatrics. In: Hooper D.C., and Rubinstein E. (Eds). Quinolone antimicrobial agents. 3rd ed. (2003), ASM Press, Washington, DC 343-354
49. Schaad U. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am 19 (2005) 617-628
50. Leibovitz E. The use of fluoroquinolones in children. Curr Opin Pediatr 18 (2006) 64-70
51. Committee of Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics 118 (2006) 1287-1292